Alnylam Pharma (ALNY) Misses Q1 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Alnylam Pharmaceuticals Reports First Quarter 2016 Financial Results and Highlights Recent Period Progress
May 2, 2016 4:00 PM EDTAdvances Pipeline of Ten Clinical Stage Programs, with Ten Additional Clinical Data Readouts Anticipated This Year
Expects to Complete Enrollment of Revusiran Phase 3 ENDEAVOUR Trial in Late 2016 with Data Readout in Mid-2018
On Track to Start Fitusiran Phase 3 Program in Mid-2016; Plans to Report Updated Hemophilia Patient Data in July
Provides Update on ALN-CC5 Program and Development Path Forward; Plans to Present Initial Data in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients in June
Ends Quarter with $1.2 Billion in Cash and Increases Year-End Cash Guidance to Over $1 Billion, Including $150 Million of Restricted... More
